(7r)-4,7-Dihydroxy-N,N,N-Trimethyl-10-Oxo-3,5,9-Trioxa-4-Phosphaheptacosan-1-Aminium 4-Oxide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: (7r)-4,7-Dihydroxy-N,N,N-Trimethyl-10-Oxo-3,5,9-Trioxa-4-Phosphaheptacosan-1-Aminium 4-Oxide
• 英文别名: 2-[hydroxy-[(2R)-2-hydroxy-3-octadecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium
• 化学式: C26H55NO7P+
• 分子量: 524.7
• InChiKey: IHNKQIMGVNPMTC-RUZDIDTESA-O

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  35
• 可旋转键数：
  26
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] BIOMARKER IN OSSOTIDE INTERVENTION THERAPY OF OSTEOPOROSIS, SCREENING METHOD, AND USE<br/>[FR] BIOMARQUEUR DANS UNE THÉRAPIE D'INTERVENTION D'OSSOTIDE DE L'OSTÉOPOROSE, PROCÉDÉ DE CRIBLAGE ET UTILISATION<br/>[ZH] 骨肽干预治疗骨质疏松中的生物标志物、筛选方法及用途
  申请人：INSTITUTE OF FOOD SCIENCE AND TECH CHINESE ACADEMY OF AGRICULTURAL SCIENCES

  公开号：WO2021114717A1

  公开（公告）日：2021-06-17

  骨肽干预治疗骨质疏松中的生物标志物、生物标志物的筛选方法及其用途。生物标志物包括脂类和类脂分子、有机酸及其衍生物和/或神经递质类物质，脂类和类脂分子为以下物质的任一种或几种：牛磺酸、花生四烯酸、1-棕榈酰-2-羟基-sn-甘油-3-磷酸乙醇胺、(4Z,7Z,10Z,13Z,16Z,19Z)-4,7,10,13,16,19-二十二碳六烯酸、1-硬脂酰-2-羟基-sn-甘油-3-磷酸胆碱、牛磺酸脱氧胆酸、牛磺去氧胆酸和牛磺胆。
• IMPROVED PROMOTERS AND COMPOSITIONS
  申请人：Oxford University Innovation Limited

  公开号：EP3423579A1

  公开（公告）日：2019-01-09
• PROCESS FOR THE PREPARATION OF UNILAMELLAR LIPOSOMAL COMPOSITION
  申请人：SUN PHARMA ADVANCED RESEARCH COMPANY LTD

  公开号：US20170087089A1

  公开（公告）日：2017-03-30

  The present invention relates to a process for the preparation of unilamellar liposomal composition of a polyene antibiotic drug. The present invention further relates to liposomal composition of a polyene antibiotic drug that is stable.
• COMPOUNDS AND METHODS FOR MANAGING CANCER THROUGH IMMUNE SYSTEM
  申请人：AKAMARA THERAPEUTICS, INC.

  公开号：US20220168261A1

  公开（公告）日：2022-06-02

  The present disclosure relates to methods of managing cancer by modulating/inhibiting cap methyltransferase enzyme. The modulation/inhibition is carried out by pharmacological or biological inhibitors, including but not limited to compounds of formula (VIII) or Compound A or A-1. Thus, the present disclosure relates to such inhibitors including compounds of formula (VIII) and their use for management of cancer. In some aspects, the compound of formula (VIII) is Compound 1. The present disclosure also relates to methods of activating B cells or T cells via modulation of cap methyltransferases. The present disclosure also relates to methods of managing cancer with a molecule or biologic that generates unmethylated RNA. The generation of unmethylated RNA activates B cells and presents the RNA to B-cell receptor (BCR). The present disclosure therefore also relates to management of cancer by activating B cells and then adoptively transferring the B cells to exert an anticancer effect.
• [EN] COMPOUNDS AND METHODS FOR MANAGING CANCER THROUGH IMMUNE SYSTEM<br/>[FR] COMPOSÉS ET MÉTHODES DE GESTION DU CANCER PAR LE BIAIS D'UN SYSTÈME IMMUNITAIRE
  申请人：AKAMARA THERAPEUTICS INC

  公开号：WO2020168283A1

  公开（公告）日：2020-08-20

  The present disclosure relates to methods of managing cancer by modulating/inhibiting cap methyltransferase enzyme. The modulation/inhibition is carried out by pharmacological or biological inhibitors, including but not limited to compounds of formula (VIII) or Compound A or A-1. Thus, the present disclosure relates to such inhibitors including compounds of formula (VIII) and their use for management of cancer. In some aspects, the compound of formula (VIII) is Compound 1. The present disclosure also relates to methods of activating B cells or T cells via modulation of cap methyltransferases. The present disclosure also relates to methods of managing cancer with a molecule or biologic that generates unmethylated RNA. The generation of unmethylated RNA activates B cells and presents the RNA to B-cell receptor (BCR). The present disclosure therefore also relates to management of cancer by activating B cells and then adoptively transferring the B cells to exert an anticancer effect.